All good points. We could always also get new CART and/or vaccine IND's
"3). The PRGN-2009 trial has been going almost two years. Last November, almost a year ago, they said the enrollment in the phase 2 study was underway. For Helen to talk about expecting a "regulatory path forward" for PRGN-2009 perhaps by year end has to be a possible "clue" that Helen thinks the data is good. Look for an update in the November Investor presentation."
I think it was pretty clear that the path forward for 2009 is the combo therapy and not the mono in Phase 2. The combo is the best therapy(did substantially better than keytruda only even on patients that had already failed Keytruda) and there is no reason to have either Keytruda or 2009 in mono form as a first line of defense. They are going for the combo as the new first line. Maybe someday adjutant patients will be given only the vaccine.
